InhaleRx secures A$38.5m deal to accelerate pain and mental health breakthroughs
Melbourne-based healthcare innovator InhaleRx Limited (ASX: IRX) has secured a substantial funding deal worth up to AUD 38.5 million, aiming to revolutionize the treatment of ... Read More
Novus Therapeutics begins phase 1 trial of OP0201 in otitis media
Novus Therapeutics has launched a phase 1 pharmacodynamics clinical trial for its promising candidate, OP0201, aimed at treating otitis media—a common middle ear infection. The ... Read More